Depression: all studies (page 61) - The Consciousness Library

Serum inflammatory cytokines in the progression of depression.

Frontiers in Immunology 2026 Qing Feng, Zhen Yuan, Qi An et al. 1 citation

Depression is increasingly recognized as a multifactorial disorder in which immune dysregulation contributes substantially to disease initiation, progression, and treatment response. Among the immune mediators implicated, serum inflammatory cytokines-including IL-1β, IL-6, TNF-α, IFN-γ, and C-reactive protein-have emerged as key links between peripheral inflammation and central nervous system...

DOI: 10.3389/fimmu.2026.1808989 Full text Depression Il-1β Tnf-α Inflammatory cytokines +2

Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in Pharmacology 2026 Yang Qu, Shujin Li, Li Tian et al.

This study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing. PubMed, Embase, the Cochrane Library, the Mainland China Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI) and Wanfang databases...

DOI: 10.3389/fphar.2026.1792570 Full text Esketamine Treatment-resistant depression Dose-dependent Meta-analysis +1

Ketamine alters the aperiodic EEG exponent in major depression: implications for cortical E/I balance and treatment prediction.

Therapeutic Advances in Psychopharmacology 2026 Yujuan Liu, Xiaorong Liu, Sebastian Olbrich et al.

Ketamine has emerged as a promising rapid-acting antidepressant for treatment-resistant depression (TRD), yet its mechanisms of action and reliable biomarkers of treatment response remain poorly understood. Recent evidence suggests that the aperiodic exponent (1/f slope) of electroencephalography (EEG) power spectra reflects cortical excitation-inhibition balance (EIB), offering a potential...

DOI: 10.1177/20451253261462240 Full text Ketamine E/i balance EEG Aperiodic exponent +1

The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.

Frontiers in Psychiatry 2026 Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço et al.

This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of...

DOI: 10.3389/fpsyt.2026.1726909 Full text Ayahuasca Mental disorders Psychedelics Psychotherapy +1

New Antidepressant Development in the Treatment of Depression.

Advances in experimental medicine and biology 2026 Alessandro Spiti, Daniela Caldirola, Giampaolo Perna 1 citation

Major depressive disorder (MDD) continues to pose a major therapeutic challenge due to its clinical heterogeneity. This chapter looks at the development of antidepressant treatments, starting with early interventions such as electroconvulsive therapy (ECT), monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Although these treatments targeted the monoaminergic system,...

DOI: 10.1007/978-981-95-6872-7_23 Full text Antidepressants Artificial intelligence Drug development Gabaergic system +3

Psychedelics: Future Therapeutics in Major Depression?

Advances in experimental medicine and biology 2026 Berend Olivier, Jocelien D A Olivier

Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...

DOI: 10.1007/978-981-95-6872-7_25 Full text Ayahuasca Ketamine Major depressive disorder Psilocybin +11

COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Genetics and Molecular Research 2026 Mahvash Khan, Muhammad Omar Malik, Sara Sajjad et al.

Background: Major depressive disorder is a prevalent psychological condition that is characterized by sustained low mood, dysfunction and biological dysregulation. Depression can be treated with cognitive behavioral therapy, and newer studies indicate that psilocybin-based therapy may improve depressive symptoms when used under supervised psychological support. Oxytocin, a neuropeptide that...

DOI: 10.4238/e91xh631

Factors for predicting response to electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and ketamine in patients with treatment-resistant depression: a systematic review

Figshare 2026 Daniel Pustay, Vishal Patel, Krista Ulisse et al. preprint

Treatment-resistant depression (TRD) remains a complex challenge, often requiring interventions beyond standard medications. This review explores factors that may predict positive response to electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and ketamine-based treatments to help guide clinical decision-making. A systematic review was conducted following PRISMA...

DOI: 10.6084/m9.figshare.31287835 Major depressive disorder Ketamine Electroconvulsive therapy Transcranial magnetic stimulation +12

Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis

Open Science Framework 2026 Annemarie van der Meij, Sotiris Poyiadis, Andrea Cipriani et al. preprint

This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depressive disorder (TRD). The project is nested within an existing network meta-analysis for TRD (NMA-TRD) project, which has already been fully specified and registered: • Muit et al., BMJ Open 2022 – protocol for a systematic review and network...

DOI: 10.17605/osf.io/k5p82 Ketamine Treatment-resistant depression Major depressive disorder Protocol science +16

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.

Annals of Medicine and Surgery 2026 Sana Rasheed, Rida Arif, Ahmed Asad Raza et al. 1 citation

Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...

DOI: 10.1097/ms9.0000000000004349 Full text Major depressive disorder Psilocybin Psychedelic therapy Clinical trials +1